Research article · 30 Jul 2026
Conference abstractPublished 8 Dec 2016
A real-world study to assess the effectiveness of Itolizumab in patients with chronic plaque psoriasis
Dr. Anchala’s Skin Clinic, India; Biocon Limited, India; Max Healthcare, India; Leelavati Hospital, India; Mallige Hospital, India
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Background: The concepts of clinical trial efficacy and real-life effectiveness are both important aspects of clinical decision making. Systematic assessment of real-life effectiveness can lend an evidence-based premise for individualization of treatment options. Realworld data on the anti-psoriatic effectiveness of Itolizumab is relatively scanty. Aims: The specific aims of this study were to assess safety and efficacy of Itolizumab therapy in patients with moderate to severe chronic plaque psoriasis. Methods: A retrospective analysis was conducted at three Indian centers between January 2014 to January 2015 to evaluate the long term safety and efficacy of Itolizumab in patients with moderate to severe chronic plaque psoriasis. At these three centers, 135 patients were prescribed Itolizumab in a dose of 1.6 mg/kg every 2 weeks for first 12 weeks followed by 1.6 mg/kg every 4 weeks up to 24 weeks. The study assessed treatment compliance, improvements in PASI scores and DLQI scores at week 12 and week 24 along with safety and tolerability assessments. Statistical analysis involved descriptive statistics and paired t-test. Results: Out of the 135 patients in the study, 40 (29.62%) received Itolizumab for 12 weeks and 23 (17.03%) patients completed the full Itolizumab regimen. The mean percent change in PASI scores at week 12 and week 24 was 75.16 (p<0.001) and 86.52 (p<0.001), respectively. Furthermore, the mean percent change in DLQI scores at week 12 and week 24 were 60.19 and 82.72, respectively. Adverse events were generally of mild to moderate severity. Limitations: Although Itolizumab therapy is safe and associated with significant improvements in PASI and DLQI scores, compliance to full treatment regimen is around 29.62%. Reasons for this low-compliance are not clear and may need additional studies. Conclusions: Itolizumab is associated with significant improvements in PASI and DLQI scores after âÂ?¥12 weeks of treatment. Only about 29.62% and 17.03% patients completed week 12 and week 24 visits respectively. Considering that adverse events were generally of mild to moderate severity, factors other than safety may be contributing to adherence. Understanding these factors may help tailor treatment plans that ensure appropriate adherence.
Subjects
DermatologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Clinical & Experimental Dermatology Research.
Commentary · 30 Jul 2026
Breaking the Stigma Around Psoriasis: A Broader View of Chronic Skin Disease
Perspective · 28 Jul 2026
Acne as More Than a Cosmetic Concern: A Personal and Medical Perspective
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Clinical & Experimental Dermatology Research
- SubjectDermatology
- BylineArticles whose byline prints “Anchala Parthsarathy”
- BylineArticles whose byline prints “Swaroop H S”
- BylineArticles whose byline prints “Vinay Singh”
- BylineArticles whose byline prints “Parasramani”
- BylineArticles whose byline prints “Krupashankar D S”
